Sen. Grassley’s bill requires disclosure of Pharma $ to doctors, ghost writers & “patient advocacy” groups like NAMI

Bipartisan legislation sponsored by Grassley to require drug, device and biologic manufacturers to report quarterly to the Department of Health and Human Services payments to physicians is part of the health care reform bill passed by the Senate Committee on Finance. The Physician Payments Sunshine Act, S.301, would establish the first-ever nationwide requirement for this information to be reported and made publicly available.
October 23, 2009

WASHINGTON — Senator Chuck Grassley is continuing his campaign to establish transparency with the financial relationships between drug companies and medical professionals.

Grassley has conducted oversight and sought disclosure with physicians, especially those involved in influential taxpayer-sponsored medical research; medical journals containing ghostwritten articles; medical colleges; continuing medical education; and the patient advocacy community.

This week, the senator released a letter seeking information from state-level chapters of the National Alliance on Mental Illness. The inquiry follows one Grassley made earlier this year asking NAMI and other patient advocacy groups and medical professional societies for information about financial relationships with drug companies and medical device manufacturers. The letter is posted with this news release at and

“Public trust and public dollars are at stake,” Grassley said. “People rely on medical advice and taxpayers spend billions of dollars on prescription drugs and devices through Medicare and Medicaid. Public confidence could be greatly improved if financial relationships were disclosed. My legislative effort is a common-sense reform that would require the pharmaceutical and device industry to report the money it gives to doctors.”

Read entire article: